Biosimilar Manufacturing Issues Should Be Focus Of User Fee Program, Firms Say
Executive Summary
Manufacturing issues will need the most attention in biosimilar applications and FDA should structure its user fee and review system to reflect it, several potential biosimilar sponsors said.
You may also be interested in...
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.
Biosimilar User Fees Would Be Same As BLAs, Only Earlier
FDA's proposed biosimilar product development fee would be charged upon IND submission, but subtracted from marketing application fee.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: